Drug Trial Radar · NCT05978492
A Study of TXN10128 in Subjects With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Jul 27, 2023
Primary completion
Dec 31, 2025
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Txinno Bioscience Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I clinical trial to primarily evaluate the safety, tolerability, and addtionally assess pharmacokinetics, pharmacodynamics, and antitumor activity of investigational product, TXN10128. The target subjects will be consisted of patients with locally advanced (unresectable) or metastatic soild tumors. This study includes a dose-escalation part and a dose-expansion part, and a TXN10128 monotherapy part and a TXN10128 + Irinotecan or Paclitaxel combination therapy part.
Conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
Interventions
TXN10128Drug
TXN10128: Oral administration once daily everyday
IrinotecanDrug
Intravenous (IV) administration at 150 mg/m2 twice (Day 1 and Day 15) at intervals of 2 weeks in one cycle
PaclitaxelDrug
IV administration at 80 mg/m2 three times (Day 1, Day 8, and Day 15) at intervals of 1 week in one cycle (IV administration at 90 mg/m2 for patients with breast cancer)
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: Day 1 up to Day 21 for Cohort A(TXN10128 mono cohort) and Day 1 up to Day 28 for Cohort B,C(TXN10128 combination with Irinotecan or paclitaxel cohort) in dose escalation period
- Adverse events (AE)Time frame: Up to 30 days from end of treatment
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Gachon University Gil Medical Center
Incheon, South Korea · Recruiting
SAMSUNG Medical Center
Seoul, South Korea · Recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Chungbuk National University Hospital
Cheonju, North Chungcheong, South Korea · Recruiting
Seoul National Univ. Hospital
Seoul, Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.